Stockscreener 앱 받기
89.50
2.08%
1.82
전일 마감가:
$87.68
열려 있는:
$88
하루 거래량:
15.24M
Relative Volume:
1.19
시가총액:
$251.88B
수익:
$64.17B
순이익/손실:
$17.12B
주가수익비율:
13.30
EPS:
6.7297
순현금흐름:
$14.84B
1주 성능:
+7.82%
1개월 성능:
-7.00%
6개월 성능:
-22.86%
1년 성능:
-30.14%
1일 변동 폭
$87.01
$89.53
1주일 범위
$81.04
$89.53
52주 변동 폭
$81.04
$134.63
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
MRK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - TradingView
Why Merck (MRK) is a Great Dividend Stock Right Now - Yahoo Finance
Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034 - GlobeNewswire Inc.
INVESTOR ALERT: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Financial Times
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRK - Markets Insider
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., - GlobeNewswire
Merck president Johannes Oosthuizen sells $714,744 in stock - Investing.com
Shareholders that lost money on Merck & Co., Inc.(MRK) - GlobeNewswire
Redburn Atlantic Adjusts Price Target on Merck to $115 From $148, Maintains Buy Rating - Marketscreener.com
Merck & Co., Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsMRK - PR Newswire
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors - GlobeNewswire
LA Gardasil Trial Against Merck Bagged After 3 Weeks - Law360
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - TradingView
Merck vaccine trial delayed as RFK Jr. link creates jury concern - Los Angeles Times
August 15th Options Now Available For Merck (MRK) - Nasdaq
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Merck & Co. digs into 'junk DNA' for cancer clues in new Epitopea deal - FirstWord Pharma
Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production - PharmaVoice
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
Merck & Co., Inc. (MRK): Among the Cheap High Dividend Stocks to Invest In Now - Insider Monkey
Merck Agrees to Halt Gardasil Trial Until September -February 18, 2025 at 03:19 pm EST - Marketscreener.com
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - Marketscreener.com
Merck cancer drug Welireg approved in EU (MRK:NYSE) - Seeking Alpha
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – MRK - GlobeNewswire
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – - EIN News
Looking Into Merck & Co's Recent Short Interest - Benzinga
Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank - Seeking Alpha
Is Merck & Co., Inc. (MRK) the Best Very Cheap Stock To Buy Right Now? - Yahoo Finance
Europe Approves Merck's Cancer Drug For Two Indications - Yahoo Finance
Exclusive-Merck vaccine case linked to HHS Secretary Kennedy delayed, company says - Marketscreener.com
Merck Gets Conditional Approval in EU for Drug Treating Von Hippel-Lindau Disease - Marketscreener.com
DBS Bank Adjusts Price Target on Merck to $100 From $168 -February 18, 2025 at 10:23 am EST - Marketscreener.com
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Merck: EU approves WELIREG treatment -February 18, 2025 at 10:16 am EST - Marketscreener.com
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock - Benzinga
Deutsche Bank Downgrades Merck to Hold From Buy, Cuts Price Target to $105 From $128 - Marketscreener.com
Merck & Co., Inc. (MRK): Among the Best Drug Stocks to Buy Now - Insider Monkey
Merck's SWOT analysis: stock faces challenges amid gardasil setback, pipeline potential - Investing.com
Merck Downgrade Sparks Urgent Investor Decisions: Time to Shift Focus? - MotoPaddock
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Jim Cramer Comments on Merck & Co., Inc. (MRK) and Its China Woes - MSN
Is Merck & Co., Inc. (MRK) the Most Oversold S&P 500 Stock in 2024? - Yahoo Finance
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Insider trades: Merck, McDonald's among notable names this week (NYSE:MRK) - Seeking Alpha
MRK INVESTOR NOTICE: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Accretive Wealth Partners LLC Makes New $531,000 Investment in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Empire Life Investments Inc. - MarketBeat
Rhumbline Advisers Cuts Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Valeo Financial Advisors LLC Has $8.83 Million Stake in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Red Cedar Investment Management LLC - MarketBeat
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.90%
자본화:
|
볼륨(24시간):